1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

13.45
USD
-1.65
(-10.96%)
13.74BMarket Cap
Apr 01Next Earn
Sino Biopharmaceutical Limited
OTC:SBHMY
(OTC Markets)

Recent

price

13.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
4.25
5.6
7.24
9.28
11.87
14.62
16.25
17.78
22.53
25.78
25.17
28.63
27.96
28.29
31.57
35.38
- -
Revenue per Share
0.59
0.45
0.86
0.97
1.45
1.79
1.96
2.6
9.76
2.94
2.95
15.57
2.73
2.52
3.83
2.6
- -
Basic EPS, GAAP
0.13
0.77
0.98
0.93
1.59
0.96
2.52
2.73
3.67
3.82
3.69
3.7
4.9
4.71
5.71
8.43
- -
Free Cash Flow per Basic Share
0.41
0.38
0.19
0.23
0.31
0.3
0.45
0.54
0.77
0.87
1.26
1
1.36
0.68
2.02
1.67
- -
Dividend per Share
3.72
3.72
4.43
5.14
6.34
7.79
9.48
11.05
13.78
15.84
17.76
32.17
32.23
33.23
35.68
34.3
32.17
Book Value per Share
3.58
3.62
4.31
5.01
6.08
7.48
9.16
10.68
10.44
13.08
16.69
30.35
30.15
30.06
32.26
26.41
30.35
Tangible Book Value per Share
819
835
834
834
834
834
834
834
927
940
940
938
931
926
914
900
940
Basic Weighted Avg Shares
3,482
4,680
6,036
7,737
9,898
12,184
13,543
14,819
20,889
24,234
23,647
26,861
26,026
26,199
28,866
31,834
- -
Sales/Revenue/Turnover
26.79
16.39
18.49
17.8
18.43
19.55
20.38
22.01
20.68
21.45
18.2
16.21
21.05
23.23
21.94
21.67
- -
Operating Margin (%)
73
110
144
175
207
296
317
343
1,176
1,446
1,655
993
1,047
1,074
1,321
1,212
- -
Depreciation Expense
483
375
717
810
1,210
1,489
1,637
2,171
9,046
2,762
2,771
14,608
2,544
2,332
3,500
2,343
- -
Net Income, GAAP
20.98
16.72
17.71
16.59
15.71
15.47
14.83
12.92
6.09
15.86
13.41
10.54
13.36
14.74
9.34
23.46
- -
Effective Tax Rate (%)
13.87
8
11.88
10.47
12.22
12.22
12.09
14.65
43.31
11.4
11.72
54.38
9.77
8.9
12.12
7.36
- -
Profit Margin (%)
2,501
1,698
2,257
2,537
3,454
3,697
7,076
8,092
8,798
16,790
11,851
8,158
5,784
1,199
5,129
9,266
8,158
Working Capital
108
28
16
- -
1,030
257
1,679
2,210
555
7,926
12,628
5,532
4,258
1,373
2,080
7,651
5,532
LT Debt
3,666
3,866
4,658
5,646
7,051
8,742
10,678
12,611
17,779
20,561
22,420
37,729
37,944
38,170
42,774
42,086
37,729
Total Equity
22.55
16.35
27.15
34.46
23.33
23.75
32.85
18.89
54.57
17.15
11.24
8.91
9.41
9.96
9.05
9.33
- -
Return on Invested Capital (%)
22.78
2.21
6.95
4.42
7.94
6.42
5.11
5.16
40.74
3.68
4.5
29.78
0.9
-0.02
1.75
-0.75
- -
Return on Capital (%)
18.28
12.06
21.11
20.31
25.28
25.29
22.75
25.37
81.39
19.75
17.49
62.11
8.47
7.74
11.21
7.48
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'21
Jun'21
Dec'21
ST Debt
1,225
1,846
6,585
LT Borrowings
12,317
11,516
5,213
LT Finance Leases
264
291
320
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
943
943
942
Market Capitalization
120,950
127,198
87,266

Working Capital

CNY

•

in mil. unless spec.
Mar'21
Jun'21
Dec'21
Total Current Assets
21,791
23,813
23,503
Cash, Cash Equivalents & STI
10,337
10,443
15,794
Accounts Receivable, Net
3,251
5,059
3,275
Inventories
1,813
1,732
1,938
Total Current Liabilities
10,358
11,485
15,345
Payables & Accruals
- -
- -
- -
ST Debt
1,225
1,846
6,585
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.58%
15.98%
-1.61%
Free Cash Flow
31.52%
18.44%
45.35%
Net Income, GAAP
64.34%
70.66%
-33.04%
Sales/Revenue/Turnover
10.68%
6.32%
10.28%
Total Cash Common Dividend
32.64%
27.45%
-18.62%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
26,199
2024
- -
- -
28,866
2025
- -
- -
31,834

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
2.52
2024
- -
- -
3.83
2025
- -
- -
2.6

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.68
2024
- -
- -
2.02
2025
- -
- -
1.67
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Sino Biopharmaceutical Limited (1177.HK) is an investment holding company engaged in the research, development, manufacture, and sale of Chinese medicines and Western medicines. The company operates through segments including Chinese medicines, Western medicines, investment management, medical aesthetics, and others; its core products and services encompass a wide range of pharmaceuticals such as anti-tumor drugs, cardio-cerebral vascular drugs, anti-infective medicines, and traditional Chinese medicine formulations including QiKangSu oral liquid and Kanglaite injection, alongside medical aesthetic products and healthcare services. Founded in 1999 and headquartered in Hong Kong, the company primarily serves the healthcare markets in the People's Republic of China with international distribution in select regions. In recent developments, Sino Biopharmaceutical has pursued strategic expansions including partnerships for innovative drug development and commercialization, alongside ongoing investments in R&D for new oncology and chronic disease therapies within the last two years.

Company News

Company News APIChatGPT

  • reuters.com

    Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

  • wsj.com

    AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

  • reuters.com

    Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

  • reuters.com

    Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln

  • forbes.com

    Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea

  • seekingalpha.com

    Week In Review: JD Health Raises $3.5 Billion In Hong Kong IPO, Climbs 56% On First Day